ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
375 |
168K |
73 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
375
|
168K
|
73
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
375 |
168K |
107 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
375
|
168K
|
107
|
|
ASX - By Stock
|
MSB |
Re:
Back pain trial
|
|
Phaedrus
|
35 |
9.7K |
6 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
35
|
9.7K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Pick Today's Price Range Low-High... Just for Fun
|
|
Phaedrus
|
1.3K |
409K |
3 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
1.3K
|
409K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Phaedrus
|
132 |
42K |
11 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
132
|
42K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Phaedrus
|
132 |
42K |
22 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
132
|
42K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
408K |
7 |
27/07/24 |
27/07/24 |
ASX - By Stock
|
943
|
408K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
otherperspective
|
675 |
306K |
52 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
675
|
306K
|
52
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
otherperspective
|
675 |
306K |
34 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
675
|
306K
|
34
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Phaedrus
|
675 |
306K |
25 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
675
|
306K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
otherperspective
|
675 |
306K |
53 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
675
|
306K
|
53
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
otherperspective
|
675 |
306K |
97 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
675
|
306K
|
97
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
375 |
168K |
57 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
375
|
168K
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
375 |
168K |
67 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
375
|
168K
|
67
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
375 |
168K |
117 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
375
|
168K
|
117
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
10K |
3.4M |
67 |
21/07/24 |
21/07/24 |
ASX - By Stock
|
10K
|
3.4M
|
67
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
10K |
3.4M |
112 |
21/07/24 |
21/07/24 |
ASX - By Stock
|
10K
|
3.4M
|
112
|
|
ASX - By Stock
|
MSB |
Re:
CLBP Trial 2024
|
|
Phaedrus
|
13 |
5.8K |
38 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
13
|
5.8K
|
38
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.4M |
6 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
10K
|
3.4M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
10K |
3.4M |
71 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
10K
|
3.4M
|
71
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
10K |
3.4M |
108 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
10K
|
3.4M
|
108
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.4M |
0 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
10K
|
3.4M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.4M |
4 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
10K
|
3.4M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
once approved
|
|
Phaedrus
|
131 |
55K |
20 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
131
|
55K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
once approved
|
|
Phaedrus
|
131 |
55K |
14 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
131
|
55K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
105K |
5 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
265
|
105K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
5.8K |
2.9M |
13 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
5.8K
|
2.9M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
105K |
6 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
265
|
105K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
105K |
16 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
265
|
105K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
105K |
21 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
265
|
105K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
408K |
2 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
943
|
408K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
408K |
21 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
943
|
408K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to File BLA for Ryoncil FDA Approval Next Week
|
|
otherperspective
|
181 |
80K |
62 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
181
|
80K
|
62
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
7.0M |
55 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
18K
|
7.0M
|
55
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
5.8K |
2.9M |
4 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
5.8K
|
2.9M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
5.8K |
2.9M |
9 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
5.8K
|
2.9M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
otherperspective
|
1.0K |
442K |
126 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
1.0K
|
442K
|
126
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.4M |
24 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
10K
|
3.4M
|
24
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.4M |
6 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
10K
|
3.4M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
otherperspective
|
1.0K |
442K |
75 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
1.0K
|
442K
|
75
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
442K |
26 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
1.0K
|
442K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
85K |
18 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
85K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
85K |
5 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
85K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
85K |
2 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
85K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
85K |
6 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
85K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
85K |
11 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
85K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
85K |
2 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
85K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
442K |
7 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
442K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
442K |
9 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
442K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
442K |
8 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
442K
|
8
|
|